

## DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia. Pusat Data dan Informasi. [Online].; 2018 [cited 2018 June Monday. Available from: [www.pusdatin.kemkes.go.id](http://www.pusdatin.kemkes.go.id).
2. Longo DL. Neoplastic Disorders. In Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison's Principles of Internal Medicine 19th Edition. New York: McGraw-Hill; 2015: 467–75.
3. Ma X, Yu H. Global Burden of Cancer. The Yale Journal of Biology and Medicine. 2010 December; 79(3–4):85–94.
4. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncology. 2017 April; 3 (4):524–48.
5. Ferlay J. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int J Cancer. 2010 December; 127(12):2893–917.
6. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M. Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN. International Journal of Cancer. 2015 March; 136(5):E359–86.
7. World Health Organization. Latest global cancer data : Cancer burden rises to 18.1 million cases and 9.6 millions cancer death in 2018. International Agency for Research on Cancer. 2018 Sept; 263.
8. Casciato DA, Territo MC. Hematologic Complications. In Casciato DA, Territo MC, editors. Manual of Clinical Oncology Seventh Edition. Philadelphia: Wolter Kluwer; 2012: 784–87.
9. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer : a systemic review of the literature. Am J Med. 2004 April; 116 Suppl 7A:11S–26S.
10. Moullet I, Salles G, Ketterer N, al. e. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol. 1998 Oct; 9(10): 1109–15.
11. Ludwig H, Van B, Barrett-Lee P, Birgerard G, Bokemayer C, Gascon P. The European Cancer Anemia Survey (ECAS): A large, multinational, prospective

- survey defining the prevalence, incidence and treatment of anaemia in cancer patients. *Eur J cancer*. 2004 Oct; 40(15):2293–306.
12. Dicato M, Piawny L, Diederich M. Anemia in cancer. *Annals of Oncology*. 2010 Oct; 21 Suppl 7:167–72.
  13. Gilreath J, Stenehjem D, Rodgers G. Diagnosis and Treatment of cancer-related anemia. *American Journal of Hematology*. 2014 February; 89(2): 203–12.
  14. Schwartz R. Anemia in patients with cancer : incidence, causes, impact, management, and use of treatment guidelines and protocols. *Am J Health Syst Pharm*. 2007 Feb; 64(3 Suppl 2):S5–13.
  15. Steensma R. Is anemia of cancer different from chemotherapy-induced anemia? *J Clin Oncol*. 2008 Mar; 26(7): 1022–4.
  16. Wilson J, Yao G, Raftery J, al. e. A systemic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. *Health Technol Assess*. 2007 Apr; 11(13):1–202.
  17. Groopman J, Itri L. Chemotherapy-Induced anemia in adults : Incidence and treatment. *JNCI*. 1999; 91(19): 1616–34.
  18. National Comprehensive Cancer Network. Cancer-and Chemotherapy-Induced Anemia. *National Comprehensive Cancer Network*. 2018 Feb; 10: 628–35.
  19. Peerschke EI, Pessin MS, Maslak P. Using the Hemoglobin Content of Reticulocytes (RET-He) to Evaluate Anemia in Patients with Cancer. *Am J Clin Pathol*. 2014 October; 142(4): 506–12.
  20. Thomas D, Hinchliffe R, Briggs C, Macdougall I, Littlewood T. Guideline for the laboratory diagnosis of functional iron deficiency. *British Journal of Haematology*. 2013 Jun; 161(5): 639–48.
  21. Chinese Society of Clinical Oncology. Expert Commite on Cancer-related Anemia. *Chinese Clinical Oncology*. 2012 Dec;1(2):18.
  22. Madeddu C, Gramignano G, Astaro G, Demontis R, Sanna E, Atzeni V, et al. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. *Frontiers in Physiology*. 2018 September; 9(1294): 1–20

23. World Health Organization. Assessing the iron status of populations: Including literature reviews : report of a Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level, Geneva, Switze. 2007 April.
24. Mehta S, Goyal L, Kaushik D, Gulati S, Sharma N, Harshvardhan , et al. Reticulocyte Hemoglobin vis-a-vis Serum Ferritin as a Marker of Bone Marrow Iron Store in Iron Deficiency Anemia. *Journal of The Association of Physicians of India*. 2016 November;64(11):38–42
25. Vela D, Gaxha Z. Differential regulation of hepcidin in cancer and non cancer tissues and its clinical implications. *Experimental & Molecular Medicine*. 2018 February; 50(2):e436.
26. Murray R, Jacob M, Varghese J. Plasma proteins & Immunoglobulin. In Murray R, Bender D, Botham K, Kennelly P, Rodwell V, Weil P, editors. *Harper's illustrated biochemistry 30<sup>th</sup> edition*. New York: McGraw-Hill; 2015. 711–34
27. Shu T, Jing C, Zhigang L, Yuchun X, Jiaren X, Jianzhong W. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. *European Journal of Haematology*. 2014 June; 94(1): 67–73.
28. Goodnough L, Nemeth E. Iron Deficiency and Related Disorders. In Greer J, Arber D, Glader B, List A, Means R, Paraskevas F, et al., editors. *Wintrobe's Clinical Hematology Thirteenth Edition*. Philadelphia: Lippincott Williams&Wilkins; 2014: 617– 42.
29. Wendy P, Anton J, Wiegerinck E, Rudi G, Swinkels D, Gussekloo J. Plasma hepcidin levels and anemia in old age. The Leiden 85-plus study. *Haematologica*. 2013 April; 98(3):448–54.
30. Piva E, Brugnara C, Spolaore F, Plebani M. Clinical utility of reticulocyte parameters. *Clin Lab Med*. 2015 Mar; 35(1):133–63.
31. Canals C, Rernacha A, Sarda M, Piazuolo J, Royo M, Romero M. Clinical utility of the new Sysmex XE 2100 parameter-reticulocyte hemoglobin equivalent- in the diagnosis of anemia. *Haematologica*. 2005 Aug; 90(8):1133–4.
32. Rehu M, Ahonen S, Punnonen K. The diagnostic accuracy of the percentage of hypochromic red blood cells (%HYPOm) and cellular hemoglobin in



- reticulocytes (CHr) in differentiating iron deficiency anemia and anemia of chronic disease. *Clin Chim Acta*. 2011 Sep; 412(19-20): 1809–13.
33. Van Wyck DB, Alcorn H, Gupta R. Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis. *Am J Kidney Dis*. 2010 Sep; 56(3): 540–6.
34. Karlsson T. Comparative evaluation of the reticulocyte hemoglobin content assay when screening for iron deficiency in elderly anemic patients. *Anemia*. 2011 Jul; 2011: 1–3.
35. Mast A, Blinder M, Lu Q, Flax S, Dietzen D. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. *Blood*. 2002 Feb; 99(4):1489–91.
36. Markovic M, Majkid-Singh N, Subota V, Mijuskovic Z. Reticulocyte hemoglobin content in the diagnosis of iron deficiency anemia. *Clinical Laboratory*. 2004; 50(7–8): 431–6.
37. Hall J. Red Blood Cells, Anemia, and Polycythemia. In Hall J, editor. *Guyton and Hall Textbook of Medical Physiology Thirteenth Edition*. Philadelphia: Elsevier; 2016: 445–54.
38. Doty R, Phelps S, Shadle C, Sanchez-Bonilla M, Keel S, Abkowitz J. Coordinate expression of heme and globin is essential for effective erythropoiesis. *J.Clin.Invest*. 2015 Dec; 125(12): 4681–91.
39. Chiabrando D, Mercurio S, Tolosano E. Heme and erythropoiesis : more than a structural role. *Haematologica*. 2014 Jun; 99(6): 973–83.
40. Bakta I. Pendekatan terhadap pasien anemia. In Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setiyohadi B, Syam A, editors. *Buku Ajar Ilmu Penyakit Dalam Edisi Keenam Jilid 2*. Jakarta: Interna Publishing; 2014. p. 2575–82.
41. European Society for Medical Oncology. Anemia in Cancer. *ESMO Handbook of Oncological Emergencies*. 2016: 197
42. Means R, Glader B. Anemia : General Considerations. In Greer J, Arber D, Glader B, List A, Means R, Paraskevas F, et al., editors. *Wintrobe's Clinical Hematology*. Philadelphia: Lippincott Williams & Wilkins; 2014: 587–616.
43. Rinaldi I, Sudoyo A. Anemia Hemolitik Non Auto Imun. In Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setiyohadi B, Syam A, editors. *Buku Ajar Ilmu*

- Penyakit Dalam Edisi Keenam Jilid 2. Jakarta: Interna Publishing; 2014: 2614–22.
44. Puthenparambil J, Lechner K, Kornek G. Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors : A critical analysis of 52 cases reported in the literature. *Win Klin Wochenschrift*. 2010 Apr; 122(7–8): 229–36.
45. Zanella A, Barcellini W. Treatment of Autoimmune Hemolytic Anemias. *Hematologica*. 2014 Oct; 99(10): 1547–54.
46. Sarper N, Kilic S, Zengin E, Aylan S. Management of autoimmune hemolytic anemia in children and adolescent : a single centre experience. *Turk J Hematology*. 2011 Aug; 28(3): 198–205.
47. Widjanarko A, Sudoyo A, Solonder H. Anemia aplastik. In Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setiyohadi B, Syam A, editors. *Buku Ajar Ilmu Penyakit Dalam Edisi Keenam Jilid 2*. Jakarta: Interna Publishing; 2014: 2646–56.
48. Hoffbrand A, Moss P. Aplastic Anemia. In Hoffbrand A, Moss P, editors. *Essential Haematology 7th Edition*. West Sussex: Wiley Blackwell; 2015: 269–76.
49. Paquette R, Munker R. Aplastic Anemia. In Munker R, Hiller E, editors. *Modern Hematology Biology and Clinical Management 2nd ed*. New Jersey: Humana Press; 2001: 207–16.
50. Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, et al. Iron Metabolism and Iron Supplementation in Cancer Patients. *Wiener Klinische Wochenschrift*. 2015 November; 127(23–24): 907–19.
51. Caiguo Z, Fan Z. Iron homeostasis and tumorigenesis : molecular mechanisms and therapeutic opportunities. *Protein cell*. 2015 February; 6(2): 88–100.
52. Weiss G, Goodnough L. Anemia of chronic disease. *N. Engl. J. Med*. 2005 Mar; 352(10): 1011–23.
53. Rouli N, Amalia P. Anemia Pada Penyakit Keganasan. *Sari Pediatri*. 2005 Mar; 6(4): 176–81.
54. Augusti N. Deficiency in Cancer Patients. *Rev Bras Hematol Hemol*. 2016 Jul; 38(3): 225–39.

55. Mantovani A, Allavena P, Sica A, Balkwil F. Cancer-Related Inflammation. *Nature*. 2008 Jul; 454(7203): 436–44.
56. Aapro M, Osteborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. *Annals of Oncology*. 2012 Aug; 23(8): 1954–62.
57. Malyszko J, Mysliwiec M. Heparin in anemia and inflammation in chronic kidney disease. *Kidney Blood Press Res*. 2007; 30(1): 15–30.
58. Coyne D. Heparin : clinical utility as a diagnostic tool and therapeutic target. *Kidney Int*. 2011 Aug; 80(3): 240–4.
59. Park C, Valore E, Waring A, Ganz T. Heparin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem*. 2001 Mar; 276(11): 7806–10.
60. Kemna E, Tjalsma H, Willems H, Swinkels D. Heparin : from discovery to differential diagnosis. *Haematologica*. 2008 Jan; 93(1): 90–7.
61. Swinkels D, Wetzels J. Heparin : a new tool in the management of anaemia in patients with chronic kidney disease? *Nephrol Dial Transplant*. 2008; 23: 2450–3.
62. Ganz T. Heparin, a key regulator of iron metabolism and mediator of anemia of inflammation. *Blood*. 2003 August; 102(3): 783–8.
63. Girelli D, Nemeth E, Swinkels D. Heparin in the diagnosis of iron disorders. *Blood*. 2016 June; 127(23): 2809–13.
64. Kearney S, Nemeth E, Neufeld E, Thapa D, Ganz T, Weinstein D. Urinary heparin in congenital chronic anemias. *Pediatric Blood Cancer*. 2007 Jan; 48(1): 57–63.
65. Girelli D, Trombini P, Busti F. A time course of heparin response to iron challenge in patients with HFE and TFR2 hemochromatosis. *Hematologica*. 2011 April; 96(4): 500–6.
66. Robach P, Recalcati S, Girelli D. Serum heparin levels and muscle iron protein in humans injected with low or high dose erythropoietin. *Eur J Haematol*. 2013 January; 91(1): 74–84.
67. Torti S, Torti F. Iron and Cancer : more or to be mind. *National Institute of Health*. 2013 May; 13(5): 342–55.



68. Bou-Abdallah F. The iron redox and hydrolysis chemistry of the ferritins. *Biochimica et biophysica Acta*. 2010 August; 1800(8): 719–31.
69. Dahlan M. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. 1st ed. Dahlan M, editor. Jakarta: Salemba Medika; 2013.
70. Kanuri G, Sawhney R, Varghese J, Britto M, Shet A. Iron Deficiency Anemia Coexist with Cancer Related Anemia and Adversly Impacts Quality of Life. *PlosOne*. 2016 September; 11(9): e0163817.
71. Mandadi M, Rios J, Schade A, Kloecker G. Hepcidin Levels in Patients with Lung Cancer. *Blood*. 2014; 124: 4889.
72. Naoum F. Iron deficiency in cancer patients. *ABHH*. 2016 Oct; 38(4): 325–30.
73. Shao x et al. The clinical value of hepcidin in breast cancer and its bone metastasis. *Ann Clin Lab*. 2017 March, 47(2): 120–8.
74. Tesfay L, Clausen K, Kim J, Hegde P, Wang X, Miller L, et al. Hepcidin regulation in prostate and its disruption in prostate cancer. *Cancer Res*. 2015 June; 75(11): 2254–63.
75. Chen Z, Zhu B, Ou C, Li Y. Serum ferritin and primary lung cancer. *Oncotarget*. 2017 Nov; 8(54): 92634–51.
76. Toki Y, Ikuta K, Yamamoto M, Hatayama M, Shindo M, Fujiya M, et al. Usefulness of Reticulocyte Hemoglobin Equivalent for Diagnosis of Iron Deficiency. *Blood*. 2016 September; 128(1): 3621.
77. Pan X, Lu Y, Wang J. Hepcidin and ferroportin expression in breast cancer tissue and serum and their relationship with anemia. *Oncology*. 2016 February; 23(1): e24–e26.
78. Maccio A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi M, et al. The role of inflammation, iron, and nutritional status in cancer related anemia : results of a large, prospective, observational study. *Haematologica*. 2015 January; 100(1):124–32.